The company's research has discovered that the cytokines targeted by CAN10, namely IL-1, IL-33, and IL-36, are significantly elevated in the skin samples of systemic sclerosis patients.

Lantern Pharma's AI-driven drug candidate, LP-284, has entered a Phase 1 clinical trial, marking a significant step in the fight against cancer.

A recent clinical trial has shown promising results for the treatment of Fanconi Anemia (FA) using a new antibody therapy named briquilimab.

Recent updates from the BEXMAB clinical trial indicate a positive trend in the treatment of high-risk (HR) myelodysplastic syndrome (MDS) patients who have not responded to hypomethylating agents (HMA).

In Thousand Oaks, California, AliveGen USA Inc. has announced the successful conclusion of its Phase 1b multiple-ascending dose (MAD) clinical trial for the novel drug ALG-801.

Rezatapopt is a groundbreaking targeted therapy for advanced solid tumors with the TP53 Y220C mutation and KRAS wild-type.

Gunda Georg, co-creator of YCT-529, presented an update on the phase 1a clinical trial of the novel hormone-free male contraceptive pill at the American Chemical Society's Spring Meeting in New Orleans

DepYmed Inc. has announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) to begin phase 1 clinical trials for DPM-1003.

Recce Pharmaceuticals has recently completed a new phase of clinical trials for its lead drug candidate, RECCE® 327.

The trial is assessing the efficacy of Deltacel™ (KB-GDT-01), an allogeneic, readily available Gamma Delta T-cell (GDT) therapy for patients with stage 4 metastatic non-small cell lung cancer (NSCLC).

Biotechnology firm Jasper Therapeutics has initiated its Phase 1b/2a clinical trial, for the treatment of chronic inducible urticaria (CIndU) using a novel antibody, briquilimab.

Celularity Inc. has submitted an application to the U.S. Food and Drug Administration (FDA) for orphan drug designation for PDA-002, its placental-derived cell therapy.